Continuous glucose monitoring systems are real-time
monitoring systems for checking glucose levels in the body. The system consists
of a tiny sensor inserted under the skin to test glucose levels in the tissue
fluid. The sensor stays in place for several days to a week and then must be
replaced. A transmitter sends information about glucose levels via radio waves
from the sensor to a pager-like wireless monitor. The key advantage of
continuous glucose monitoring is that it can help identify fluctuations and
trends that would otherwise go unnoticed with standard HbA1c tests and
intermittent finger stick measurements.
Development in the multi-parameter mid-range patient
monitoring devices can create a new opportunity for further expansion.
Collaboration with established local companies can be helpful for manufacturers
to provide effective services and maintain profit margins simultaneously.
Further cost reduction by integration of continuous glucose monitors with
insulin pumps can be helpful for CGMs to achieve significant popularity among
the price sensitive Asian consumers.
The CGM systems market is a highly specialized niche
market; it can be further segmented into the market for transmitters-receivers
and the one for glucose. The U.S. is contributing the maximum in terms of the
total revenue earned from CGMs. The European market is still in a nascent stage
and contributes a small amount to the total revenue. The Asia-Pacific region
and Brazil also contribute very little to the global revenues.
The CGM systems markets in the U.S and Europe are
growing at a fast pace and estimated to reach to a three digit (in USD million)
market size globally at a CAGR of double digits. The rapid increase in the
number of diabetes patients is the major driving force for the estimated
growth. The most important driver for the CGM market in Europe is the need for
a convenient, affordable, and patient-friendly device that facilitates superior
therapy management for diabetes and this need can be fulfilled by CGM devices.
In the present
scenario, the slow growth rate of the market in the Asian region is due to the
late launch of CGM systems and a slow acceptance of these systems in low and
middle income nations such as China and India due to the unaffordable price. In
Japan and Australia, various regulatory approvals are a hindrance for the
growth of the market.
Some of the market players in this industry include
Medtronic Inc., DexCom Inc., Abbott Diabetes Care Inc and others.
This research report analyzes this market depending on
its market segments, major geographies, and current market trends. Geographies
analyzed under this research report include
North America
Asia Pacific
Europe
Rest of the World
This report provides comprehensive analysis
of
Market growth
drivers
Factors limiting market
growth
Current market
trends
Market structure
Market projections for
upcoming years
This report is a complete study of current trends in
the market, industry growth drivers, and restraints. It provides market
projections for the coming years. It includes analysis of recent developments
in technology, Porter’s five force model analysis and detailed profiles of top
industry players. The report also includes a review of micro and macro factors
essential for the existing market players and new entrants along with detailed
value chain analysis.
Browse
All Market Research Report : http://www.transparencymarketresearch.com/
Browse
Bolg : http://globalmarketresearchreports.wordpress.com/
